It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In this work, we introduce a one-step strategy that is suitable for continuous flow manufacturing of antimicrobial PDMS materials. The process is based on the intrinsic capacity of PDMS to react to certain organic solvents, which enables the incorporation of antimicrobial actives such as salicylic acid (SA), which has been approved for use in humans within pharmaceutical products. By combining different spectroscopic and imaging techniques, we show that the surface properties of PDMS remain unaffected while high doses of the SA are loaded inside the PDMS matrix. The SA can be subsequently released under physiological conditions, delivering a strong antibacterial activity. Furthermore, encapsulation of SA inside the PDMS matrix ensured a diffusion-controlled release that was tracked by spatially resolved Raman spectroscopy, Attenuated Total Reflectance IR (ATR-IR), and UV-Vis spectroscopy. The biological activity of the new material was evaluated directly at the surface and in the planktonic state against model pathogenic bacteria, combining confocal laser scanning microscopy, electron microscopy, and cell viability assays. The results showed complete planktonic inhibition for clinically relevant strains of Staphylococcus aureus and Escherichia coli, and a reduction of up to 4 orders of magnitude for viable sessile cells, demonstrating the efficacy of these surfaces in preventing the initial stages of biofilm formation. Our approach adds a new option to existing strategies for the antimicrobial functionalisation of a wide range of products such as catheters, wound dressings and in-dwelling medical devices based on PDMS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Liverpool & National Biofilm Innovation Centre, Open Innovation Hub for Antimicrobial Surfaces, Department of Chemistry, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); University of Liverpool, Institute of Infection and Global Health, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
2 University of Liverpool & National Biofilm Innovation Centre, Open Innovation Hub for Antimicrobial Surfaces, Department of Chemistry, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
3 University of Liverpool, Biomedical Electron Microscopy Unit, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
4 University of Liverpool, Institute of Infection and Global Health, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)